Journal of Medicinal Chemistry
Page 6 of 8
(5)
Offermanns, S. Free fatty acid (FFA) and hydroxy
FFA1 (GPR40) agonist TUGꢀ469. ACS Med. Chem. Lett. 2010, 1,
345ꢀ349.
(20) Christiansen, E.; DueꢀHansen, M. E.; Urban, C.;
carboxylic acid (HCA) receptors. Annu. Rev. Pharmacol. Toxicol.
2014, 54, 407ꢀ434.
1
2
3
4
5
6
7
8
9
(6)
Burant, C. F. Activation of GPR40 as a therapeutic target
Grundmann, M.; Schroder, R.; Hudson, B. D.; Milligan, G.;
Cawthorne, M. A.; Kostenis, E.; Kassack, M. U.; Ulven, T. Free Fatty
Acid Receptor 1 (FFA1/GPR40) Agonists: Mesylpropoxy Appendage
Lowers Lipophilicity and Improves ADME Properties. J. Med. Chem.
2012, 55, 6624ꢀ6628.
(21) Liu, J.; Wang, Y.; Ma, Z.; Schmitt, M.; Zhu, L.; Brown, S.
P.; Dransfield, P. J.; Sun, Y.; Sharma, R.; Guo, Q.; Zhuang, R.;
Zhang, J.; Luo, J.; Tonn, G. R.; Wong, S.; Swaminath, G.; Medina, J.
C.; Lin, D. C. H.; Houze, J. B. Optimization of GPR40 Agonists for
Type 2 Diabetes. ACS Med. Chem. Lett. 2014, 5, 517ꢀ521.
(22) Du, X.; Dransfield, P. J.; Lin, D. C. H.; Wong, S.; Wang,
Y.; Wang, Z.; Kohn, T.; Yu, M.; Brown, S. P.; Vimolratana, M.; Zhu,
L.; Li, A.ꢀR.; Su, Y.; Jiao, X.; Liu, J.; Swaminath, G.; Tran, T.; Luo,
J.; Zhuang, R.; Zhang, J.; Guo, Q.; Li, F.; Connors, R.; Medina, J. C.;
Houze, J. B. Improving the Pharmacokinetics of GPR40/FFA1 Full
Agonists. ACS Med. Chem. Lett. 2014, 5, 384ꢀ389.
(23) Christiansen, E.; Urban, C.; Merten, N.; Liebscher, K.;
Karlsen, K. K.; Hamacher, A.; Spinrath, A.; Bond, A. D.; Drewke, C.;
Ullrich, S.; Kassack, M. U.; Kostenis, E.; Ulven, T. Discovery of
potent and selective agonists for the free fatty acid receptor 1
(FFA1/GPR40), a potential target for the treatment of type II diabetes.
J. Med. Chem. 2008, 51, 7061ꢀ7064.
(24) Christiansen, E.; Urban, C.; Grundmann, M.; DueꢀHansen,
M. E.; Hagesaether, E.; Schmidt, J.; Pardo, L.; Ullrich, S.; Kostenis,
E.; Kassack, M. U.; Ulven, T. Identification of a potent and selective
free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable
physicochemical and in vitro ADME properties. J. Med. Chem. 2011,
54, 6691–6703.
(25) Christiansen, E.; DueꢀHansen, M. E.; Urban, C.;
Grundmann, M.; Schmidt, J.; Hansen, S. V. F.; Hudson, B. D.; Zaibi,
M.; Markussen, S. B.; Hagesaether, E.; Milligan, G.; Cawthorne, M.
A.; Kostenis, E.; Kassack, M. U.; Ulven, T. Discovery of a Potent and
Selective Free Fatty Acid Receptor 1 Agonist with Low Lipophilicity
and High Oral Bioavailability. J. Med. Chem. 2013, 56, 982−992.
(26) Christiansen, E.; Hansen, S. V. F.; Urban, C.; Hudson, B.
D.; Wargent, E. T.; Grundmann, M.; Jenkins, L.; Zaibi, M.; Stocker,
C. J.; Ullrich, S.; Kostenis, E.; Kassack, M. U.; Milligan, G.;
Cawthorne, M. A.; Ulven, T. Discovery of TUGꢀ770: A Highly
Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for
Treatment of Type 2 Diabetes. ACS Med. Chem. Lett. 2013, 4, 441ꢀ
445.
(27) Christiansen, E.; DueꢀHansen, M. E.; Ulven, T. A rapid and
efficient Sonogashira protocol and improved synthesis of free fatty
acid 1 (FFA1) receptor agonists. The J. Org. Chem. 2010, 75, 1301ꢀ
1304.
(28) Christiansen, E.; Urban, C.; Merten, N.; Liebscher, K.;
Karlsen, K. K.; Hamacher, A.; Spinrath, A.; Bond, A. D.; Drewke, C.;
Ullrich, S.; Kassack, M. U.; Kostenis, E.; Ulven, T. Discovery of
potent and selective agonists for the free fatty acid receptor 1
(FFA(1)/GPR40), a potential target for the treatment of type II
diabetes. J. Med. Chem. 2008, 51, 7061ꢀ7064.
for the treatment of type 2 diabetes. Diabetes Care 2013, 36 Suppl 2,
S175ꢀ179.
(7)
Vakilynejad, M.; Xie, B.; Leifke, E. TAKꢀ875 versus placebo or
glimepiride in type 2 diabetes mellitus: a phase 2, randomised,
doubleꢀblind, placeboꢀcontrolled trial. Lancet 2012, 379, 1403ꢀ1411.
Burant, C. F.; Viswanathan, P.; Marcinak, J.; Cao, C.;
(8)
Kaku, K.; Enya, K.; Nakaya, R.; Ohira, T.; Matsuno, R.
Efficacy and safety of fasiglifam (TAKꢀ875), a G proteinꢀcoupled
receptor 40 agonist, in Japanese patients with type 2 diabetes
inadequately controlled by diet and exercise: a randomized, doubleꢀ
blind, placeboꢀcontrolled, phase III trial. Diabetes Obes. Metab. 2015,
17, 675ꢀ681.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
(9)
Tomita, T.; Masuzuaki, H.; Iwakura, H.; Fujikura, J.;
Noguchi, M.; Tanaka, T.; Ebihara, K.; Kawamura, J.; Komoto, I.;
Kawaguchi, Y.; Fujimoto, K.; Doi, R.; Shimada, Y.; Hosoda, K.;
Imamura, M.; Nakao, K. Expression of the gene for a membraneꢀ
bound fatty acid receptor in the pancreas and islet cell tumours in
humans: evidence for GPR40 expression in pancreatic beta cells and
implications for insulin secretion. Diabetologia 2006, 49, 962ꢀ968.
(10) Tomita, T.; Hosoda, K.; Fujikura, J.; Inagaki, N.; Nakao, K.
The Gꢀproteinꢀcoupled longꢀchain fatty acid receptor GPR40 and
glucose metabolism. Front. Endocrinol. 2014, 5, 152.
(11) Hauge, M.; Vestmar, M. A.; Husted, A. S.; Ekberg, J. P.;
Wright, M. J.; Di Salvo, J.; Weinglass, A. B.; Engelstoft, M. S.;
Madsen, A. N.; Lückmann, M.; Miller, M. W.; Trujillo, M. E.;
Frimurer, T. M.; Holst, B.; Howard, A. D.; Schwartz, T. W. GPR40
(FFAR1) – Combined Gs and Gq signaling in vitro is associated with
robust incretin secretagogue action ex vivo and in vivo. Mol. Metab.
2015, 4, 3ꢀ14.
(12) Defossa, E.; Wagner, M. Recent developments in the
discovery of FFA1 receptor agonists as novel oral treatment for type 2
diabetes mellitus. Bioorg. Med. Chem. Lett. 2014, 24, 2991ꢀ3000.
(13) Srivastava, A.; Yano, J.; Hirozane, Y.; Kefala, G.;
Gruswitz, F.; Snell, G.; Lane, W.; Ivetac, A.; Aertgeerts, K.; Nguyen,
J.; Jennings, A.; Okada, K. Highꢀresolution structure of the human
GPR40 receptor bound to allosteric agonist TAKꢀ875. Nature 2014,
513, 124ꢀ127.
(14) Leeson, P. D.; Springthorpe, B. The influence of drugꢀlike
concepts on decisionꢀmaking in medicinal chemistry. Nat. Rev. Drug
Discov. 2007, 6, 881ꢀ890.
(15) Waring, M. J. Lipophilicity in drug discovery. Expert Opin.
Drug Discov. 2010, 5, 235ꢀ248.
(16) Waring, M. J.; Arrowsmith, J.; Leach, A. R.; Leeson, P. D.;
Mandrell, S.; Owen, R. M.; Pairaudeau, G.; Pennie, W. D.; Pickett, S.
D.; Wang, J.; Wallace, O.; Weir, A. An analysis of the attrition of
drug candidates from four major pharmaceutical companies. Nat. Rev.
Drug Discov. 2015, 14, 475ꢀ486.
(17) Negoro, N.; Sasaki, S.; Mikami, S.; Ito, M.; Tsujihata, Y.;
Ito, R.; Suzuki, M.; Takeuchi, K.; Suzuki, N.; Miyazaki, J.; Santou,
T.; Odani, T.; Kanzaki, N.; Funami, M.; Morohashi, A.; Nonaka, M.;
Matsunaga, S.; Yasuma, T.; Momose, Y. Optimization of (2,3ꢀ
Dihydroꢀ1ꢀbenzofuranꢀ3ꢀyl)acetic Acids: Discovery of a NonꢀFree
Fatty AcidꢀLike, Highly Bioavailable G ProteinꢀCoupled Receptor
40/Free Fatty Acid Receptor 1 Agonist as a GlucoseꢀDependent
Insulinotropic Agent. J. Med. Chem. 2012, 55, 3960–3974.
(18) Mikami, S.; Kitamura, S.; Negoro, N.; Sasaki, S.; Suzuki,
M.; Tsujihata, Y.; Miyazaki, T.; Ito, R.; Suzuki, N.; Miyazaki, J.;
Santou, T.; Kanzaki, N.; Funami, M.; Tanaka, T.; Yasuma, T.;
Momose, Y. Discovery of Phenylpropanoic Acid Derivatives
Containing Polar Functionalities as Potent and Orally Bioavailable G
ProteinꢀCoupled Receptor 40 Agonists for the Treatment of Type 2
Diabetes. J. Med. Chem. 2012, 55, 3756–3776.
(29) Christiansen, E.; Hansen, S. V.; Urban, C.; Hudson, B. D.;
Wargent, E. T.; Grundmann, M.; Jenkins, L.; Zaibi, M.; Stocker, C. J.;
Ullrich, S.; Kostenis, E.; Kassack, M. U.; Milligan, G.; Cawthorne,
M. A.; Ulven, T. Discovery of TUGꢀ770: A Highly Potent Free Fatty
Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2
Diabetes. ACS Med. Chem. Lett. 2013, 4, 441ꢀ445.
(30) Ulven, T.; Christiansen, E. Dietary Influences on
Regulation of the LongꢀChain Fatty Acid Receptor FFA4/GPR120.
Annu. Rev. Nutr. 2015, 35, 239ꢀ263.
(31) Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency:
a useful metric for lead selection. Drug Discov. Today 2004, 9, 430ꢀ
431.
(32) Hopkins, A. L.; Keseru, G. M.; Leeson, P. D.; Rees, D. C.;
Reynolds, C. H. The role of ligand efficiency metrics in drug
discovery. Nat. Rev. Drug Discov. 2014, 13, 105ꢀ121.
(19) Christiansen, E.; DueꢀHansen, M. E.; Urban, C.; Merten,
N.; Pfleiderer, M.; Karlsen, K. K.; Rasmussen, S. S.; Steensgaard, M.;
Hamacher, A.; Schmidt, J.; Drewke, C.; Petersen, R. K.; Kristiansen,
K.; Ullrich, S.; Kostenis, E.; Kassack, M. U.; Ulven, T. Structureꢀ
activity study of dihydrocinnamic acids and discovery of the potent
(33) Shultz, M. D. Improving the Plausibility of Success with
Inefficient Metrics. ACS Med. Chem. Lett. 2014, 5, 2ꢀ5.
ACS Paragon Plus Environment